State Board of Administration of Florida Retirement System Has $120,000 Stock Position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

State Board of Administration of Florida Retirement System boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH – Get Rating) (TSE:AUP) by 6.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 27,860 shares of the biotechnology company’s stock after purchasing an additional 1,660 shares during the period. State Board of Administration of Florida Retirement System’s holdings in Aurinia Pharmaceuticals were worth $120,000 as of its most recent filing with the SEC.

Several other hedge funds have also bought and sold shares of AUPH. Bellevue Group AG acquired a new stake in Aurinia Pharmaceuticals in the 1st quarter valued at about $29,784,000. State Street Corp raised its holdings in Aurinia Pharmaceuticals by 355.5% in the 2nd quarter. State Street Corp now owns 2,387,862 shares of the biotechnology company’s stock valued at $23,998,000 after acquiring an additional 1,863,594 shares during the period. Renaissance Technologies LLC raised its holdings in Aurinia Pharmaceuticals by 262.7% in the 1st quarter. Renaissance Technologies LLC now owns 1,694,200 shares of the biotechnology company’s stock valued at $20,974,000 after acquiring an additional 1,227,129 shares during the period. Northern Trust Corp raised its holdings in Aurinia Pharmaceuticals by 897.3% in the 2nd quarter. Northern Trust Corp now owns 1,019,317 shares of the biotechnology company’s stock valued at $10,244,000 after acquiring an additional 917,113 shares during the period. Finally, Armistice Capital LLC bought a new position in Aurinia Pharmaceuticals in the 3rd quarter valued at about $5,444,000. 40.36% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Aurinia Pharmaceuticals

In other news, CFO Joseph M. Miller sold 11,296 shares of Aurinia Pharmaceuticals stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total transaction of $100,986.24. Following the transaction, the chief financial officer now owns 331,214 shares in the company, valued at $2,961,053.16. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Joseph M. Miller sold 11,296 shares of the business’s stock in a transaction on Thursday, March 2nd. The shares were sold at an average price of $8.94, for a total value of $100,986.24. Following the transaction, the chief financial officer now owns 331,214 shares in the company, valued at $2,961,053.16. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director David R.W. Jayne sold 8,733 shares of the business’s stock in a transaction on Tuesday, May 23rd. The shares were sold at an average price of $11.26, for a total transaction of $98,333.58. Following the completion of the transaction, the director now owns 49,310 shares in the company, valued at approximately $555,230.60. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 72,453 shares of company stock worth $668,436. Company insiders own 3.70% of the company’s stock.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH opened at $11.31 on Wednesday. The company’s 50 day simple moving average is $10.62 and its 200 day simple moving average is $8.13. The stock has a market capitalization of $1.62 billion, a price-to-earnings ratio of -16.88 and a beta of 1.18. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.07 and a 1 year high of $13.41.

Aurinia Pharmaceuticals (NASDAQ:AUPH – Get Rating) (TSE:AUP) last issued its earnings results on Thursday, May 4th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05. Aurinia Pharmaceuticals had a negative net margin of 65.90% and a negative return on equity of 23.56%. The firm had revenue of $34.41 million for the quarter, compared to analyst estimates of $28.12 million. During the same quarter last year, the business posted ($0.27) earnings per share. The company’s quarterly revenue was up 59.1% on a year-over-year basis. As a group, analysts anticipate that Aurinia Pharmaceuticals Inc. will post -0.71 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have weighed in on AUPH. StockNews.com began coverage on shares of Aurinia Pharmaceuticals in a report on Thursday, May 18th. They issued a “hold” rating on the stock. Royal Bank of Canada raised their target price on shares of Aurinia Pharmaceuticals from $11.00 to $13.00 and gave the stock an “outperform” rating in a report on Tuesday, May 2nd. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $13.00.

Aurinia Pharmaceuticals Profile

(Get Rating)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis.